Google
Trusted Resources: News & Events
Latest announcements and gatherings
Gene Therapy for Blood Disorders
In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field, enabling you to progress your pipeline to address the significant unmet need in this field.
Focused specifically on hemophilia, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches, this event is an invaluable opportunity to learn the realities of durability challenges, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field.
Date:
March 29 – 31, 2022
This event has ended.
+myBinderRelated Content
-
National Sickle Cell Disease Poll of African Americans Dispels Long-Held ViewsPfizer Inc. (NYSE:PFE), the National New...
-
Sickle Beta Plus Thalassemia DiseaseSickle Beta + Thalassemia (Sickle BA-ta ...
-
Beta Thalassemia TraitWhat is beta thalassemia trait? Beta th...
-
P.O.W.E.R ECHO Project Community Health Worker (CHW) Training – 3/21/24Cost: Free Monthly sessions 12–1 p.m...
-
Bluebird Bio Presents Data From LentiGlobin Gene Therapy TrialBluebird Bio’s investigational gene th...
-
Sickle cell gene linked to elevated risk of developing kidney failureNew research indicates that being born w...
-
RARE Patient Advocacy SummitEach year, Global Genes convenes one of ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.